Skystar Bio Pharmaceutical Company (NasdaqCM:SKBI) is seeking acquisitions. Bing Mei, Chief Financial Officer of Skystar, Bio said, "we are in contract with a third party to look for the kind of strategic acquisition opportunity to acquire the technology to acquire the other business". Scott Cramer, Director Corporate Development & US Representative, Skystar Bio, said, "To be clear, we have not identified acquisition targets but we have placed on deposit with the third-party company for lack of a better term, earnest money, so they know we are serious.

Since we have not identified a target we cannot say how long we will be looking."